OwlTail

Cover image of Oncology Times Broadcast News
(3)
Health & Fitness
Medicine
Science

Oncology Times Broadcast News

Updated 25 days ago

Health & Fitness
Medicine
Science
Read more

In collaboration with Audio Journal of Oncology, OT now features audio-reports and interviews about new clinical research from major cancer meetings and key journals.The programs are created by the leading medical audioservice worldwide, Audio Medica, whose Audio Journal of Oncology has been bringing these lively listen-in shows to members of the cancer care team in various audio formats since 1992.Scientific Editors are: George Canellos, MD, of Dana-Farber Cancer Institute; J. Gordon McVie, MD, of the European Institute of Oncology and Chair of the Editorial Board of OT's UK Edition; Pat Price, MD, of Christie Hospital, also on the OTUK Editorial Board; and Gianni Bonadonna, MD, of Istituto Nazionale Tumori.

Read more

In collaboration with Audio Journal of Oncology, OT now features audio-reports and interviews about new clinical research from major cancer meetings and key journals.The programs are created by the leading medical audioservice worldwide, Audio Medica, whose Audio Journal of Oncology has been bringing these lively listen-in shows to members of the cancer care team in various audio formats since 1992.Scientific Editors are: George Canellos, MD, of Dana-Farber Cancer Institute; J. Gordon McVie, MD, of the European Institute of Oncology and Chair of the Editorial Board of OT's UK Edition; Pat Price, MD, of Christie Hospital, also on the OTUK Editorial Board; and Gianni Bonadonna, MD, of Istituto Nazionale Tumori.

iTunes Ratings

3 Ratings
Average Ratings
1
0
0
0
2

iTunes Ratings

3 Ratings
Average Ratings
1
0
0
0
2

Best weekly hand curated episodes for learning

Cover image of Oncology Times Broadcast News

Oncology Times Broadcast News

Latest release on Oct 06, 2009

Best weekly hand curated episodes for learning

The Best Episodes Ranked Using User Listens

Updated by OwlTail 25 days ago

Rank #1: Metastatic Colorectal Cancer: Capecitabine Equivalent to 5-FU in Irinotecan/Bevacizumab Combos

Podcast cover
Read more
Oncology Times Broadcast News:

Metastatic Colorectal Cancer: Capecitabine Equivalent to 5-FU in Irinotecan/Bevacizumab Combos

Adding the oral drug capecitabine to a regimen of bevacizumab plus irinotecan was as effective as adding infusions of 5FU/folinic acid for patients who had metastatic colorectal cancer in a phase II study presented to the World Congress on Gastrointestinal Cancer in Barcelona (24-27 June, 2009; Abstract: 0-0013). Michel Ducreux, Head of the Gastrointestinal Service at the Institut Gustave Roussy in Villejuif, Paris, discussed the new evidence and its clinical implications with Peter Goodwin.

Sep 28 2009

6mins

Play

Rank #2: "Promising Activity" Of Cetuximab In Patients With Advanced Biliary Cancer

Podcast cover
Read more
BARCELONA, SPAIN—Adding cetuximab to gemcitabine/oxaliplatin (GEMOX) chemotherapy controlled disease among two thirds of patients with advanced biliary cancer in a trial reported at the World Congress on Gastrointestinal Cancer. Éveline Boucher from the Centre Eugene Marquis, in Rennes, France, presented preliminary findings from a phase II open-label study among 101 patients who had not already received palliative treatment for their advanced biliary cancers, and had WHO performance status 0-1.
She discussed her team’s findings with Peter Goodwin.

Sep 28 2009

2mins

Play

Similar Podcasts

Oncology Data Advisor

Oncology Congress

PeerVoice Oncology & Haematology Audio

Disease State - Oncology/Genomics

Clinical Oncology Podcast

Cancer Grand Rounds Lectures from the Norris Cotton Cancer Center Podcasts

Breast Cancer CancerCare Connect Education Workshops

All CancerCare Connect Education Workshops

Cancer Conference Update

JCO Oncology Practice Podcast

JAMA Oncology Author Interviews

Dermatologic Oncology Update

Thyroid Cancer Update

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

Rank #3: Stage IV Pancreatic Islet Cell Tumors: Sunitinib Monotherapy Increased Progression Free Survival

Podcast cover
Read more
Oncology Times Broadcast News:

Stage IV Pancreatic Islet Cell Tumors: Sunitinib Monotherapy Increased Progression Free Survival
Treatment of advanced pancreatic islet cell tumors with sunitinib has doubled progression-free survival in patients whose options have been very limited up to now, according to French researchers reporting their phase III randomized study findings at the World Congress on Gastrointestinal Cancer in Barcelona (24-27 June, 2009; ABSTRACT: 0-0013). Eric Raymond from Beaujon University Hospital, Villejuif, France, gave Peter Goodwin his clinical interpretation of the findings.

Sep 28 2009

4mins

Play

Rank #4: Colorectal Cancer: KRAS-Driven Selection Of Molecular Therapy Could Save Millions: Bevacizumab, Cetuximab, Panitumomab, or Combinations?

Podcast cover
Read more
11th Annual Palm Beach Cancer Symposium (April 3-4, 2009 Hollywood, Florida)—Peter Goodwin interviews John Macdonald, Chief Medical Officer of Aptium Oncology in Los Angeles about his data on the relevance of KRAS tumor status to the choice of molecular therapy for patients with metastatic colorectal cancer. Whether the gene is wild-type or mutant determines sensitivity of the tumor to anti-epidermal growth factor or anti-vascular endothelial growth factor receptor therapy. Dr Macdonald also discusses the disappointing finding that blocking both of these proliferation pathways does not lead to improved efficacy when two targeted drugs are used in combination.

Sep 28 2009

3mins

Play

Most Popular Podcasts

The Joe Rogan Experience

TED Talks Daily

The Tim Ferriss Show

The Daily

Stuff You Should Know

Oprah's SuperSoul Conversations

Armchair Expert with Dax Shepard

Rank #5: Chronic Myeloid Leukemia 'To Become A Very Indolent Disease': Pregnancy Possible, Transplants Avoided—Mission Accomplished?

Podcast cover
Read more
11th Annual Palm Beach Cancer Symposium (April 3-4, 2009 Hollywood, Florida)—Peter Goodwin interviews Hagop Kantarjian MD from the MD Anderson Cancer Center in Houston about his latest findings on treating CML in patients who have the T315I mutation. He also discusses the feasibility of patients becoming pregnant while having tyrosine kinase inhibitor (TKI) treatment (among those who have achieved stability for at least two years); and talks about the decreased need for allogeneic transplant.

Sep 28 2009

9mins

Play

Rank #6: Oropharyngeal Carcinoma: Better Outlook From Human Papilloma Virus-Directed Therapies— Different Patient Characteristics, New Therapeutic Opportunities

Podcast cover
Read more
11th Annual Palm Beach Cancer Symposium (April 3-4, 2009 Hollywood, Florida)—Peter Goodwin interviews Marshall Posner MD from the Dana-Farber Cancer Institute in Boston about the increased prevalence of oropharygeal cancers which are related to HPV infection. These tumors may be less aggressive than cancers testing negative for HPV, and have proved more responsive to the most effective modern therapies which use docetaxel along with cisplatin and fluorouracil for induction prior to standard chemo-radiotherapy. He discusses the need for biological agents and drugs directed against the human papilloma virus which is essential for maintaining malignant phenotype and the urgency of vaccinating 12 to 24 year olds to reduce the pool of infection.

Sep 28 2009

6mins

Play

Rank #7: Bilateral Prophylactic Mastetomy For DCIS

Podcast cover
Read more
Oncology Times Broadcast News with the Audio Journal of Oncology

Reporting from: 10th European Congress Perspectives in Lung Cancer, Brussels March 6-7, 2009 and Journal of Clinical Oncology

Bilateral Prophylactic Mastetomy For DCIS

Todd Tuttle from the University of Minnesota in Minneapolis and Abram Recht from Harvard Medical School and the Beth Israel Deaconess Medical Center in Boston about the increasing use of prophylactic bilateral mastectomy, already reported in breast cancer and now revealed from the SEER database in ductal carcinoma in situ.

Apr 06 2009

10mins

Play

Rank #8: Insulin-Like Growth Factor Inhibition In Lung Cancer

Podcast cover
Read more
Oncology Times Broadcast News with the Audio Journal of Oncology

Reporting from: 10th European Congress Perspectives in Lung Cancer, Brussels March 6-7, 2009 and Journal of Clinical Oncology

Insulin-Like Growth Factor Inhibition In Lung Cancer

Silvia Novello, and Giorgio Scagliotti from the University of Turin about harnessing insulin-like growth factor receptor inhibition in a phase II study which has shown clinical activity of figitumomab at least as significant as inhibitors of other growth factors already being used in cancer.

Apr 06 2009

7mins

Play

Rank #9: Swedish Registry Study Shows Hormone Therapy for Prostate Cancer Increased All Cardiovascular Mortality

Podcast cover
Read more
Oncology Times Broadcast News

Swedish Registry Study Shows Hormone Therapy for Prostate Cancer Increased All Cardiovascular Mortality

Mieke Van Hemelrijck at ECCO15-ESMO34 on findings that cardiovascular mortality from heart failure and arrhythmia in addition to ischemic heart disease and myocardial infarction increased among patients treated with endocrine therapy—of whatever type—for their prostate cancer.

Oct 06 2009

4mins

Play

Rank #10: Aromatase Inhibitor Better Than Tamoxifen For Initial Adjuvant Therapy For Hormone Receptor Positive Breast Cancer, But Compliance An Issue!

Podcast cover
Read more
Oncology Times Broadcast News

Aromatase Inhibitor Better than Tamoxifen for Initial Adjuvant Therapy for HR- Positive Breast Cancer, But Compliance an Issue!

Cornelis van de Velde at ECCO15-ESMO34 on the largest comparison of an aromatase inhibitor with tamoxifen as initial adjuvant therapy for patients with hormone receptor-positive breast cancer–analysis of results from the TEAM (Tamoxifen Exemestane Adjuvant Multinational) study reported at ECCO15-ESMO34.

Oct 06 2009

6mins

Play